drugset / Trial / NCT00109135

A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007)

NCT00109135 ↗

Phase 2 Completed 300 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of an investigational drug that may help individuals to stop smoking.

Timeline

Start
2005-01
Primary completion
2005-06
Completion
2005-06

Outcome

Missed primary endpoint

paper Taranabant 2-8 mg did not improve smoking cessation PMID 20191360 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject taranabant Unknown 8 mg —

Indications

No indication recorded.